Epstein Secrets

ylvania School of Medicine in 1991. Agus completed his residency training at Johns Hopkins Hospital and completed his oncology fellowship training at the Memorial Sloan-Kettering Cancer Center in New York. He spent two years at the National Institutes of Health as a Howard Hughes Medical Institute-NIH Research Scholar. Agus has had a long

an attending physician in the Department of Medicine, Division of Medical Oncology at Cedars-Sinai. He was also an Associate Professor of Medicine at the University of California, Los Angeles (UCLA). He currently is a Professor of Medicine and Engineering at the Keck School of Medicine of USC and the Viterbi School of Engineering and is t

ears at the National Institutes of Health as a Howard Hughes Medical Institute-NIH Research Scholar. Agus has had a long and varied career. At the Memorial Sloan-Kettering Cancer Center in New York, he was an attending physician in the Department of Medical Oncology and head of the Laboratory of Tumor Biology. He was also Assistan

attending physician in the Department of Medicine, Division of Medical Oncology at Cedars-Sinai. He was also an Associate Professor of Medicine at the University of California, Los Angeles (UCLA). He currently is a Professor of Medicine and Engineering at the Keck School of Medicine of USC and the Viterbi School of Engineering and is

prominent shoulder blades. Melissa Spencer from the University of California, Los Angeles, who has studied calpainopathy for 14 years, expl

ancer How “exceptionalresponders’ ‘arerevolutionizing treatment for the deadly desease BY KAT MCGOWAN UST LIKE EVERY NEW drug the oncologists at Memorial Sloan-Kettering Cancer Center test- ed against bladder cancer in the last 20 years, this one didn’t seem to be doing any good. For- ty-four people in the study were given everolim